What they were paid
Beam Therapeutics Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $67,917 | $0 | $400,234 | $0 | $468,151 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Beam Therapeutics Inc. DEF 14A filed April 17, 2026, accession 0001193125-26-161512, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Beam Therapeutics pays directors a $50,000 cash retainer and $400,234 in equity.
Committees
FY2025 · as the proxy prints themAudit (Chair)
The rest of the Beam Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Carole Ho, M.D | Independent Director | $470,651 |
| Chirfi Guindo | Independent Director | $455,651 |
| Christi Shaw | Independent Director | $463,151 |
| John Evans | Director | $0 |
| John Maraganore, Ph.D | Independent Director | $465,651 |
| Kathleen Walsh | Independent Director | $465,651 |
| Mark Fishman, M.D | Lead Independent Director | $495,234 |
The full Beam Therapeutics compensation record
free company briefThis page is one director within Beam Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat